1. Home
  2. GKOS vs BTG Comparison

GKOS vs BTG Comparison

Compare GKOS & BTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$102.43

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Logo B2Gold Corp

BTG

B2Gold Corp

HOLD

Current Price

$4.76

Market Cap

6.3B

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
BTG
Founded
1998
2006
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Precious Metals
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
6.3B
IPO Year
2015
2007

Fundamental Metrics

Financial Performance
Metric
GKOS
BTG
Price
$102.43
$4.76
Analyst Decision
Strong Buy
Buy
Analyst Count
12
2
Target Price
$126.92
$6.00
AVG Volume (30 Days)
1.0M
23.7M
Earning Date
04-29-2026
05-06-2026
Dividend Yield
N/A
1.86%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$507,442,000.00
N/A
Revenue This Year
$23.32
$38.08
Revenue Next Year
$27.43
$28.46
P/E Ratio
N/A
$34.75
Revenue Growth
32.33
N/A
52 Week Low
$73.16
$3.31
52 Week High
$148.11
$6.29

Technical Indicators

Market Signals
Indicator
GKOS
BTG
Relative Strength Index (RSI) 28.38 48.83
Support Level $92.38 $4.23
Resistance Level $102.80 $4.99
Average True Range (ATR) 7.36 0.20
MACD -4.94 -0.03
Stochastic Oscillator 1.08 25.32

Price Performance

Historical Comparison
GKOS
BTG

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About BTG B2Gold Corp

B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other assets include the Gramalote gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.

Share on Social Networks: